Clinical Trial Finder

Key

Inclusion Criteria:

1. Disease criteria: 1. Histologically or cytologically confirmed recurrent/advanced (unresectable) or metastatic solid tumors or histiocytic neoplasms with documented RAS or BRAF mutations. Note: Patients may have stable central nervous system (CNS) metastases. Patients with active CNS metastases or primary CNS tumors associated with progressive neurological symptoms or needing increased doses of corticosteroids to control the CNS disease are excluded from the study. 2. Dose Escalation cohorts:

• - NSCLC with KRAS non-G12C mutations, including other mutations at KRAS-G12 (eg, G12V/G12D) or BRAF (Class I, II, or III) (with Sponsor approval).

• - Melanoma with BRAF (Class I, II, or III) or NRAS mutations.

• - Histiocytic neoplasms with BRAF (Class I, II, or III) or NRAS mutations.

• - Thyroid carcinoma with BRAF (Class I, II, or III) mutations.

• - Colorectal carcinoma with BRAF (Class II or III) mutations with Sponsor approval.

• - Other solid tumors with BRAF Class I mutations after prior treatment with a BRAF/MEK inhibitor or local standard-of-care with Sponsor approval.

3. Dose Expansion cohort: Recurrent advanced/metastatic NSCLC with KRAS non-G12C mutations without small cell lung cancer transformation with progressive disease confirmed by radiographic assessment. 2. Received prior standard-of-care: 1. Exhausted all available standard-of-care therapies or, in the opinion of the Investigator, would be unlikely to tolerate or derive clinically meaningful benefit from available standard-of-care therapy. 2. Patients with eligible tumors harboring BRAF V600E mutations that have received FDA approved BRAF targeted therapy, BRAF/MEK inhibitors combination, or BRAF inhibitors combination. 3. Evaluable or measurable disease in dose escalation and measurable disease only for dose expansion cohorts. 4. Adequate bone marrow and organ function. 5. Recovered from toxicity to prior anti-cancer therapy. 6. Appropriate candidate for BDTX-4933 monotherapy. 7. Life expectancy of >=12 weeks in the opinion of the Investigator. Key

Exclusion Criteria:

1. Cancer that has a known MEK1/2 mutation. 2. Major surgery within 4 weeks of study entry or planned during study. 3. Ongoing anticancer therapy. 4. Ongoing radiation therapy. 5. Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy. 6. Symptomatic spinal cord compression. 7. Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years. 8. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO. 9. Females who are pregnant or breastfeeding. 10. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study. 11. Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway.

Arms

Experimental: Phase 1 Dose Escalation

BDTX-4933 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached and the preliminary recommended Phase 2 dose (RP2D) is determined.

Experimental: Phase 1 Dose Expansion

BDTX-4933 will be administered at the RP2D.

Interventions

Drug: - BDTX-4933

RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active KRAS or NRAS mutations